Table 1.
Demographic characteristics of subjects at screening.
| NOMAC/E2 | DRSP/EE | Total | |
|---|---|---|---|
| N | 1591 | 535 | 2126 |
| Age | |||
| Mean years (SD) | 28(7) | 28 (7) | 28 (7) |
| 18-35 years n (%) | 1319 (82.9%) | 443 (82.8%) | 1762 (82.9%) |
| 36-50 years n (%) | 272 (171%) | 92 (172%) | 364 (171%) |
| Race n (%) | |||
| Asian | 77 (4.8%) | 26 (4.9%) | 103 (4.8%) |
| Black/African American | 4 (0.3%) | 3 (0.6%) | 7 (0.3%) |
| White/Caucasian | 1501 (94.3%) | 501 (93.6%) | 2002 (94.2%) |
| Other | 9 (0.6%) | 5 (0.9%) | 14 (0.7%) |
| Ethnicity n (%)14 | |||
| Missing | 1 | 0 | 1 |
| Hispanic or Latino | 15 (0.9%) | 8 (1.5%) | 23 (1.1%) |
| Not Hispanic or Latino | 1575 (99.1%) | 527 (98.5%) | 2102 (98.9%) |
| Body weight, mean kg (SD) | 63.4 (10.5) | 63.7 (10.1) | 63.5 (10.4) |
| BMI, mean kg/m2 (SD) | 23.0 (3.5) | 23.0 (3.4) | 23.0 (3.5) |
| Smoking n (%) | 381 (24.0%) | 146 (273%) | 527 (24.8%) |
| Contraceptive method at screening n (%) | |||
| None | 155 (9.7%) | 58 (10.8%) | 213 (10.0%) |
| COC | |||
| All | 1072 (674%) | 356 (66.5%) | 1428 (672%) |
| DRSP/EE only | 281 (177%) | 73 (13.6%) | 354 (16.7%) |
| Foam, condom, suppositories, diaphragm | 255 (16.0%) | 83 (15.5%) | 338 (15.9%) |
| POP | 34 (2.1%) | 16 (3.0%) | 50 (2.4%) |
| Hormonal ILJD | 10 (0.6%) | 5 (0.9%) | 15 (0.7%) |
| Non-hormonal ILJD | 14 (0.9%) | 6 (1.1%) | 20 (0.9%) |
| NuvaRing® | 28 (1.8%) | 5 (0.9%) | 33 (1.6%) |
| Patch | 6 (0.4%) | 4 (0.7%) | 10 (0.5%) |
NOMAC/E2, nomegestrol acetate/17β-oestradiol (NOMAC/E2); DRSP/EE, drospirenone/ethinylestradiol (DRSP/EE); BMI, body mass index; COC, combined oral contraceptive; POP progestogen-only pill; ILJD, intrauterine device; POP progestogen-only pill; SD, standard deviation.